Relmada Therapeutics (RLMD) Short-Term Debt issuances (2019 - 2020)
Relmada Therapeutics (RLMD) posted quarterly Short-Term Debt issuances of -$110247.0 for Q1 2020, down 28.24% year-over-year from -$153633.8 in Q2 2019, and up 50.57% quarter-over-quarter from -$223017.0 in Q3 2019.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Short-Term Debt issuances (2019 - 2020) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Short-Term Debt issuances for 2 consecutive years, with -$110247.0 the latest figure, recorded in Q1 2020.
- In Q1 2020, Short-Term Debt issuances fell 28.24% year-over-year to -$110247.0; the TTM figure through Sep 2020 stood at -$333264.0 (changed N/A YoY), while the FY2019 annual figure was -$285170.0, down 3454.94% from the prior year.
- Short-Term Debt issuances grew to -$110247.0 in Q1 2020 per RLMD's latest filing, from -$223017.0 in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at -$85969.0 in Q1 2019 and bottomed at -$223017.0 in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | -110,247.00 |
| Sep 30, 2019 | -223,017.00 |
| Jun 30, 2019 | -114,738.00 |
| Mar 31, 2019 | -85,969.00 |